Jones Day Partner David Alden co-authors Drug & Device Product Liability Litigation Strategy (2nd ed.)
As federal and state courts continue to be inundated with lawsuits seeking recovery from pharmaceutical companies and medical device manufacturers, those companies – and their legal representatives – need direction and counsel that can help them evaluate their potential strategies, options, and courses of action. Drug & Device Product Liability Litigation Strategy (2d ed. Oxford Univ. Press 2018), co-authored by Jones Day Business & Tort Litigation partner David Alden, offers detailed background, discussion, and strategic guidance to in-house and outside counsel involved in these high-stakes matters.
The second edition of Drug & Device Product Liability Litigation Strategy, offers an analysis of the full range of issues involved in drug and device litigation, including pre-litigation counselling, document preservation and discovery, consolidation and mass joinder, multidistrict litigation, class action litigation, admissibility of expert testimony, dispositive and pre-trial motion practice, jury selection, and trial.
"Dave has produced a valuable and timely book," said Stephanie Parker, who co-leads Jones Day's Business & Tort Litigation Practice. "As litigation targeting medical device and pharmaceutical companies continues to become more complex and costly, companies facing these matters need to manage their exposure, control risk, and mitigate potential damages. Dave’s work is an exceptional resource for lawyers seeking a solid understanding of the most effective strategies."
The second edition of Drug & Device Product Liability Litigation Strategy, which Dave Alden co-authored with Mark Hermann and Geoffrey Drake, includes thorough revisions to reflect recent changes in the legal landscape following key court decisions and statutory developments in areas such as preemption, the admissibility of expert testimony, the learned intermediary doctrine, and innovator liability, and also includes new analyses of issues such as personal jurisdiction, pre-litigation counselling, and the amended Federal Rules of Civil Procedure. It is an indispensable guide to lawyers handling cases in this high-stakes, high-profile, and rapidly evolving area.
Dave Alden's litigation practice focuses on product liability matters and, in particular, on actions involving prescription drugs, medical devices, tobacco, and consumer products. He has served as pretrial, trial, and appellate counsel in matters throughout the United States and long has served as national coordinating counsel for major product liability clients.
For more information about Drug & Device Product Liability Litigation Strategy please visit Oxford University Press.
Jones Day is a global law firm with more than 2,500 lawyers in 42 offices across five continents. The Firm is distinguished by: a singular tradition of client service; the mutual commitment to, and the seamless collaboration of, a true partnership; formidable legal talent across multiple disciplines and jurisdictions; and shared professional values that focus on client needs.
